Europe · General news · Swissinfo

Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study

Published by Swissinfo · Switzerland 1 d ago

Novartis AG’s breast cancer pill Kisqali helped patients with a common form of early-stage disease live longer, bolstering the case for its use before cancer returns.

Read the full article on Swissinfo Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.swissinfo.ch)

Also worth reading

The Independent

Historic London leisure centre closes ‘until next year’ after illness-causing bacteria found

RTÉ

Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study

Share

Also worth reading

Saudi Arabia executes man for crime committed when he was 14

Storm Boelo brings 80mph gusts and travel disruption to Scotland

Mum says phone call from hospital 'felt like I’d been handed a death sentence'

Fury as Green Party activist given 'free rein by BBC' to lambast Jewish woman

Historic London leisure centre closes ‘until next year’ after illness-causing bacteria found

Where to next after Triple Lock passes first Dáil vote?